Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
A framework for tuberculosis research and development expenditure based on the return on investment criterion
Dissertation (MBA)--University of Pretoria, 2013.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
University of Pretoria
2014
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613479611924480 |
|---|---|
| access_status_str | Open Access |
| author2 | Walwyn, David |
| author_browse | Walwyn, David |
| author_facet | Walwyn, David |
| collection | Thesis |
| dc_rights_str_mv | © 2014 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. |
| description | Dissertation (MBA)--University of Pretoria, 2013. |
| format | Thesis |
| id | oai:repository.up.ac.za:2263/40641 |
| institution | University of Pretoria (South Africa) |
| language | English |
| last_indexed | 2026-06-10T12:36:48.396Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository |
| publishDate | 2014 |
| publishDateRange | 2014 |
| publishDateSort | 2014 |
| publisher | University of Pretoria |
| publisherStr | University of Pretoria |
| record_format | dspace |
| source_str | UPSpace — University of Pretoria Institutional Repository |
| spelling | oai:repository.up.ac.za:2263/40641 A framework for tuberculosis research and development expenditure based on the return on investment criterion Walwyn, David ichelp@gibs.co.za Jongihlati, Babalwa Jongihlati, Babalwa UCTD Tuberculosis Capital investments -- Evaluation Rate of return Dissertation (MBA)--University of Pretoria, 2013. Research and development (R&D) covering diseases that disproportionately affect developing nations is grossly inadequate. In particular it has been noted over a long period that governments of countries with high tuberculosis (TB) disease burden under invest in TB R&D, despite having 40% of the world’s notified TB cases. For instance, South Africa’s (SA) annual expenditure on TB R&D, of US$1,2 million in 2012, is insignificant relative to its disease burden, of 1 003 per 100,000 population. New tools are required to stop TB; these tools require R&D investment. However a recent report has noted that for the first time in eight years, global spending on TB R&D decreased in 2012 compared with the previous year. This drop in R&D investment threatens to undermine the possibility of any future insights from TB research. The important question remains: how can public investment in TB R&D be stimulated or incentivised, especially within those countries of high prevalence and sizeable R&D budgets (such as India, SA, China and Russia)? In an attempt to answer such a question, this research followed a quantitative, case study methodology based on secondary data analysis of information from the World Health Organisation (WHO) and the SA National Strategic Plan (NSP) 2012-2016, looking at the costs associated with TB treatment in SA and identified areas of potential savings as a consequence of well directed R&D. For additional information on external funding and TB R&D investment, the study used the Organisation for Economic and Development (OECD) and Treatment Action Group (TAG) data. A return on investment estimation method for suitable R&D projects was then used to compute the optimal TB R&D investment range. The results of the research show that there are higher returns on the optimization of TB drug regimens versus new drug development. The argument proposed by this research is that further TB R&D expenditure can be justified from a purely economic return on investment consideration, considering that expenditure of public funds on TB treatment is high and significant savings can be made through improvements to the current drug regimen optimisation. This report will help policy makers in increasing public health R&D expenditure from present levels to those targets set by the World Health Organisation’s Consultative Expert Working Group (CEWG) and others. This return on investment will only be realised if public-funded R&D is focussed more directly on public health priorities. lmgibs2014 Gordon Institute of Business Science (GIBS) MBA Unrestricted 2014-07-08T10:52:08Z 2014-07-08T10:52:08Z 2013-04-30 2013 Mini Dissertation Jongihlati, B 2013, A framework for tuberculosis research and development expenditure based on the return on investment criterion, MBA Mini Dissertation, University of Pretoria, Pretoria, viewed yymmdd <http://hdl.handle.net/2263/40641> http://hdl.handle.net/2263/40641 en © 2014 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria |
| spellingShingle | UCTD Tuberculosis Capital investments -- Evaluation Rate of return A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title | A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title_full | A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title_fullStr | A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title_full_unstemmed | A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title_short | A framework for tuberculosis research and development expenditure based on the return on investment criterion |
| title_sort | framework for tuberculosis research and development expenditure based on the return on investment criterion |
| topic | UCTD Tuberculosis Capital investments -- Evaluation Rate of return |
| url | http://hdl.handle.net/2263/40641 |